MedTrace Logo

Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients

NCT03453307 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-03-05

No results posted yet for this study

Summary

This clinical study aims to evaluate the feasibility to predict clinical response of target therapy or chemotherapy drugs based on the ex vivo drug sensitivity data using patient-derived organoids.

Conditions

Sponsors & Collaborators

  • K2 Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Zhijian Sun, Dr. · K2 Oncology, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2020-07-30
Completion
2021-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03453307 on ClinicalTrials.gov